CN112168874A - Action of hawthorn and mulberry on cardiovascular disease - Google Patents
Action of hawthorn and mulberry on cardiovascular disease Download PDFInfo
- Publication number
- CN112168874A CN112168874A CN201910593725.9A CN201910593725A CN112168874A CN 112168874 A CN112168874 A CN 112168874A CN 201910593725 A CN201910593725 A CN 201910593725A CN 112168874 A CN112168874 A CN 112168874A
- Authority
- CN
- China
- Prior art keywords
- hawthorn
- mulberry
- composition
- fruit
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 240000000249 Morus alba Species 0.000 title claims abstract description 60
- 235000008708 Morus alba Nutrition 0.000 title claims abstract description 60
- 235000009917 Crataegus X brevipes Nutrition 0.000 title claims abstract description 57
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 title claims abstract description 57
- 235000009685 Crataegus X maligna Nutrition 0.000 title claims abstract description 57
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 title claims abstract description 57
- 235000009486 Crataegus bullatus Nutrition 0.000 title claims abstract description 57
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 title claims abstract description 57
- 235000009682 Crataegus limnophila Nutrition 0.000 title claims abstract description 57
- 235000004423 Crataegus monogyna Nutrition 0.000 title claims abstract description 57
- 235000002313 Crataegus paludosa Nutrition 0.000 title claims abstract description 57
- 235000009840 Crataegus x incaedua Nutrition 0.000 title claims abstract description 57
- 208000024172 Cardiovascular disease Diseases 0.000 title claims abstract description 25
- 240000000171 Crataegus monogyna Species 0.000 title abstract 2
- 230000009471 action Effects 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims abstract description 30
- 208000035150 Hypercholesterolemia Diseases 0.000 claims abstract description 18
- 235000013305 food Nutrition 0.000 claims abstract description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 16
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 15
- 235000016709 nutrition Nutrition 0.000 claims abstract description 6
- 235000013361 beverage Nutrition 0.000 claims abstract description 5
- 235000015872 dietary supplement Nutrition 0.000 claims abstract description 5
- 235000013376 functional food Nutrition 0.000 claims abstract description 5
- 239000000047 product Substances 0.000 claims abstract description 5
- 229940127554 medical product Drugs 0.000 claims abstract description 4
- 241001092040 Crataegus Species 0.000 claims description 55
- 239000000843 powder Substances 0.000 claims description 28
- 208000035475 disorder Diseases 0.000 claims description 11
- 235000013399 edible fruits Nutrition 0.000 claims description 10
- 201000001320 Atherosclerosis Diseases 0.000 claims description 8
- 235000011869 dried fruits Nutrition 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 239000000284 extract Substances 0.000 claims description 8
- 235000021022 fresh fruits Nutrition 0.000 claims description 8
- 235000015094 jam Nutrition 0.000 claims description 8
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 8
- 241001465754 Metazoa Species 0.000 claims description 6
- 208000029078 coronary artery disease Diseases 0.000 claims description 5
- 235000013402 health food Nutrition 0.000 claims description 4
- 239000002417 nutraceutical Substances 0.000 claims description 4
- 235000021436 nutraceutical agent Nutrition 0.000 claims description 4
- 239000006186 oral dosage form Substances 0.000 claims description 4
- 206010051055 Deep vein thrombosis Diseases 0.000 claims description 3
- 208000010378 Pulmonary Embolism Diseases 0.000 claims description 3
- 206010047249 Venous thrombosis Diseases 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 3
- 208000004124 rheumatic heart disease Diseases 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000036541 health Effects 0.000 abstract description 5
- 208000020346 hyperlipoproteinemia Diseases 0.000 abstract description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 43
- 210000004369 blood Anatomy 0.000 description 23
- 239000008280 blood Substances 0.000 description 23
- 108010028554 LDL Cholesterol Proteins 0.000 description 11
- 235000012000 cholesterol Nutrition 0.000 description 10
- 241000699670 Mus sp. Species 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 230000002195 synergetic effect Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 5
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- 210000001367 artery Anatomy 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 231100000517 death Toxicity 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 208000032928 Dyslipidaemia Diseases 0.000 description 3
- 208000017170 Lipid metabolism disease Diseases 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- 206010011091 Coronary artery thrombosis Diseases 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 208000031481 Pathologic Constriction Diseases 0.000 description 2
- 238000003639 Student–Newman–Keuls (SNK) method Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000005189 cardiac health Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 208000002528 coronary thrombosis Diseases 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 235000009200 high fat diet Nutrition 0.000 description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 208000030613 peripheral artery disease Diseases 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000037804 stenosis Diseases 0.000 description 2
- 230000036262 stenosis Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 206010002329 Aneurysm Diseases 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 235000007106 Crataegus suborbiculata Nutrition 0.000 description 1
- 241000073432 Crataegus suborbiculata Species 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000220222 Rosaceae Species 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 206010060755 Type V hyperlipidaemia Diseases 0.000 description 1
- 235000013202 a hawthorn Nutrition 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 208000024980 claudication Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- -1 hypercholesterolemia Chemical class 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000869 mutational effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/01—Instant products; Powders; Flakes; Granules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/09—Mashed or comminuted products, e.g. pulp, purée, sauce, or products made therefrom, e.g. snacks
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a composition of hawthorn and mulberry and application thereof, which can treat, slow down or prevent hypercholesterolemia, high-low density lipoproteinemia and related cardiovascular disease disorders, and belongs to the field of health efficacy. The invention can be used for preparing food products, beverages, health-care foods, functional foods, nutritional medical foods, special medical products, nutritional formula products, dietary supplements and pet foods for treating, slowing down or preventing hypercholesterolemia, hyperlipoproteinemia and related cardiovascular diseases, and has wide application prospect.
Description
Technical Field
The invention relates to the field of health, and particularly discloses a composition of hawthorn and mulberry which are medicinal and edible raw materials, and is used for preventing, treating or relieving hyperlipidemia, hypercholesterolemia and related cardiovascular disease disorders.
Background
Cardiovascular diseases (CVDs) are the leading cause of death worldwide. According to WHO reports, 1730 million people are estimated to die of CVDs in 2008, accounting for 30% of all deaths worldwide. Of these deaths, 730 million were estimated to be due to coronary heart disease and 620 million were due to stroke. By 2030, almost 2360 million people will die of CVDs, mainly due to heart disease and stroke. These are inferred to be the single leading cause of death. In recent 30 years, the blood lipid level of Chinese people gradually rises, and the prevalence rate of dyslipidemia is obviously increased. The national survey result in 2012 shows that the Total Cholesterol (TC) of adult human serum is 4.50mmol/L on average, and the prevalence rate of hypercholesterolemia is 4.9%; triglyceride (TG) averages 1.38mmol/L, prevalence of hypertriglyceridemia 13.1%; high-density lipoprotein cholesterol (HDL-C) averages 1.19mmol/L, and the prevalence of low HDL-C blood is 33.9%. The total prevalence rate of dyslipidemia of adults in China is as high as 40.40%, which is greatly increased compared with 2002. The increase of the serum cholesterol level of the population leads to about 920 ten thousand of cardiovascular disease events in China during the period from 2010 to 2030. The hypercholesterolemia prevalence rate of children and teenagers in China is also obviously increased, which indicates that adult dyslipidemia and related disease burden in China will be continuously increased.
Hyperlipidemia is characterized by abnormally elevated levels of any or all lipids and/or lipoproteins in the blood. Hyperlipidemia can also be directly classified by the type of elevated lipids, i.e. hypercholesterolemia, hypertriglyceridemia or both in mixed hyperlipidemia. Elevated lipoprotein levels can also be classified as a form of hyperlipidemia. Hypercholesterolemia is one of the major causes of atherosclerosis or coronary heart disease.
Disorders associated with hyperlipidemia and/or hypercholesterolemia are primarily cardiovascular disorders. Cardiovascular disorders are a group of disorders of the heart and blood vessels, including coronary heart disease, cerebrovascular disease, peripheral artery disease, rheumatic heart disease, deep vein thrombosis, pulmonary embolism, and the like. "cardiovascular disorders" refers generally to any disease affecting the cardiovascular system, and in particular to those disorders associated with atherosclerosis (arterial disease). These disorders often have similar causes, mechanisms, and treatments.
Atherosclerosis is the accumulation of fatty deposits (such as cholesterol) called plaques on the inner wall of arteries. Atherosclerosis is often quite severe when cardiac problems are detected, and has progressed for decades. More commonly, the plaque suddenly ruptures, causing a thrombus to form that will rapidly block blood flow, causing the peripheral tissue to die in only 5 minutes. This mutational event is called infarction. One of the most commonly identified conditions is coronary thrombosis, known as coronary artery thrombosis, which causes myocardial infarction (heart attack). The same process in the arteries leading to the brain is commonly referred to as stroke. Another common situation in very severe disease states is claudication due to insufficient blood supply to the leg, usually caused by both stenosis and the aneurysm segment where the clot causes stenosis.
Hyperlipidemia is the most important risk factor for atherosclerosis, a major cause of cardiovascular disease. The main cause of atherosclerosis is not yet known, it is a syndrome affecting the arterial blood vessels-an inflammatory response in the arterial wall, the latter being mainly caused by the accumulation of macrophages and promoted by low density lipoproteins (LDL, plasma lipoproteins carrying cholesterol and triglycerides), without adequate removal of fat and cholesterol from macrophages by functional High Density Lipoproteins (HDL). It is commonly referred to as hardening or fouling (furring) of the arteries. This is caused by the formation of multiple plaques within the artery.
The importance of maintaining low cholesterol levels for health is now becoming increasingly appreciated. Typical measures to reduce cholesterol levels are reduction of dietary cholesterol intake, administration of certain drugs and few other treatments (even including surgery).
Disclosure of Invention
Aiming at the problems of the current hyperlipemia and/or hypercholesterolemia related disorder rising trend year by year and the like, the invention provides a composition of hawthorn and mulberry for treating, slowing down or preventing the hypercholesterolemia, the hyperlipoproteinemia and the related cardiovascular disease disorder. The present invention provides a convenient dietary way to reduce cholesterol levels.
Thus, the compositions of the invention are useful for lowering plasma total cholesterol levels, particularly plasma LDL cholesterol levels. Low LDL cholesterol concentrations reduce the risk of cardiovascular disorders.
In one aspect, the present application provides a composition comprising hawthorn and mulberry, wherein the weight ratio of hawthorn to mulberry is 5: 4.
In certain embodiments, the hawthorn and mulberry are in the form of a hawthorn dry powder and a mulberry dry powder, respectively.
In certain embodiments, the hawthorn is provided in the form of fresh fruit, jam, dried fruit, fruit powder, extracts thereof.
In certain embodiments, the morous alba is provided in the form of fresh fruit, jam, dried fruit, fruit powder, extracts thereof.
In certain embodiments, the hawthorn and mulberry are the only active ingredients.
In certain embodiments, the composition may be any composition suitable for human or animal consumption selected from the group consisting of: food products, beverages, health foods, functional foods, nutraceutical foods, specialty medical products, nutritional formula products, dietary supplements, and pet foods; alternatively, the composition may be a medicament in oral dosage forms, such as tablets, capsules and powders.
Various adjuvants and food additives conventionally used in the art may be added to the above food products, beverages, health foods, functional foods, nutraceutical foods, specialist products, nutritional formula products, dietary supplements and pet foods.
Various adjuvants and excipients, etc. conventionally used in the art may be added to the above oral dosage form of the drug.
In another aspect, the present application provides the use of the above-described composition comprising hawthorn and mulberry for the preparation of a medicament for preventing, treating or slowing hyperlipidemia, hypercholesterolemia and associated cardiovascular disease disorders; wherein the weight ratio of the hawthorn to the mulberry is 5: 4.
In certain embodiments, the cardiovascular disorder associated with hyperlipidemia and/or hypercholesterolemia includes coronary heart disease, cerebrovascular disease, peripheral artery disease, rheumatic heart disease, deep vein thrombosis and pulmonary embolism, disorders associated with atherosclerosis.
Hawthorn, a flowering shrub/small tree of the rosaceae family, has a wide history of use in cardiovascular disease, dating back to the 1 st century. Hawthorn has been shown to have promising effects on blood cholesterol lowering. Furthermore, hawthorn has a limited effect on lowering blood triglycerides, which in blood lipids is an important risk factor for cardiovascular diseases.
Mulberry (Mulberry fruit, Mulberry) is a dried ear of Mulberry (Morus alba l. of the family moraceae). Collected after the fruit turns red in 4-6 months, dried in the sun or slightly steamed and dried in the sun. Mulberry contains rich nutrients and bioactive components, such as amino acids, vitamins, minerals, polyphenol, polysaccharide, etc., and has high nutritive value. Mulberry has a series of physiological functions, such as antioxidation, weight reduction, immunoregulation, anti-tumor, cardiovascular disease prevention and the like. Therefore, morous alba has been listed as a first list of articles which are both food and medicine by the national health commission (department of health), and medicinal uses of morous alba have been recorded in the chinese pharmacopoeia.
Accordingly, the present invention is directed, in part, to hawthorn and mulberry compositions for use in treating, reducing or preventing disorders associated with hyperlipidemia and/or hypercholesterolemia.
The hawthorn and mulberry compositions of the present invention can be used to promote heart health and/or to treat, reduce or prevent impaired heart health.
The compositions of the present invention are effective according to a dose-response curve. They may be administered in a therapeutically effective dose or a prophylactically effective dose. The skilled person will be able to determine the dosage as appropriate.
Taking 65kg for example in adults, the composition of the invention may be generally formulated in a ratio corresponding to 0.14g (lower daily limit) and 0.19g (upper daily limit) of hawthorn powder per kg body weight per day, and 0.08g (lower daily limit) and 0.16g (upper daily limit) of dry mulberry powder, wherein the hawthorn powder and dry mulberry powder are mixed in a ratio of 5:4 in a ratio. For example, the composition of the present invention may comprise at least 0.14g dry hawthorn powder and at least 0.112g dry mulberry powder per kg body weight per day. Alternatively, the composition of the present invention may comprise at least 0.19g g g of hawthorn and at least 0.152g of dry mulberry powder per kg of body weight per day.
The hawthorn may be provided in any form suitable for administration to a human or animal. For example, hawthorn may be provided as fresh fruit, jam, dried fruit, fruit powder, hawthorn leaf, or as an extract thereof.
Morous alba may be provided in any form suitable for administration to a human or animal. For example, morous alba can be provided as fresh fruit, jam, dried fruit, fruit powder, morous alba leaves or as an extract thereof.
The composition may be any composition suitable for human or animal consumption.
Since disorders associated with hyperlipidemia and/or hypercholesterolemia often occur with aging, the compositions of the present invention may be administered to adults or the elderly. In addition, the hypercholesterolemia prevalence rate of children and teenagers in China is obviously increased, so the composition can be applied to the children and the teenagers, and the risks of cardiovascular diseases related to the children and the teenagers in the future are prevented and reduced.
Description of the attached tables
Table 1 combination of hawthorn and mulberry has a synergistic lowering effect on total blood cholesterol in mice fed with high fat.
Table 2. combination of hawthorn and mulberry has a synergistic lowering effect on plasma low density lipoprotein cholesterol in mice fed with high fat.
Detailed Description
Embodiments of the present invention will be described in detail below with reference to examples, but those skilled in the art will appreciate that the following examples are only illustrative of the present invention and should not be construed as limiting the scope of the present invention.
Unless specifically defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the relevant art.
1. Experimental animals and groups
50 male Balb/C mice (Shanghai slke laboratory animals Co., Ltd.) were housed in SPF animal rooms of 12 hours light/12 hours dark, 40% -70% relative humidity, room temperature 18-22 ℃ and randomly divided into 5 groups after 1 week of adaptive feeding, each group consisting of 10 mice: a control group (common feed), a high-fat group (simple high-fat feed, Research Diets inc.d12492, fat accounting for 60% of heat energy), a high-fat hawthorn group (high-fat feed with 0.1g of hawthorn powder added per day), a high-fat mulberry group (high-fat feed with 0.08g of mulberry powder added per day), and a high-fat hawthorn/mulberry combination group (high-fat feed with 0.1g of hawthorn powder and 0.08g of mulberry powder added per day).
2. Procedure of experiment
Mice were fed with different feeds. During this period rats were weighed once a week, fed (calculated energy intake) and drunk. After 12 weeks of continuous feeding, the mice were sacrificed, blood was collected and centrifuged to obtain serum, and four items of blood lipids (triglyceride, total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol) were measured.
3. Statistical analysis
All data are expressed as Mean ± standard deviation (Mean ± SD), single factor analysis of variance using SPSS19.0 software, and two-by-two comparison using SNK (Student-Newman-Keuls) method, with P <0.05 being statistically significant.
Example 1: the combination of fructus crataegi and Mori fructus can synergistically lower Total Cholesterol (TC) in animal models with high fat diet
Total cholesterol in blood: after 12 weeks of continuous feeding, the high-fat group significantly increased blood cholesterol by 10.85mmol/L compared to the control group (table 1, P < 0.01). Compared with the high-fat group, the mulberry has no obvious change on blood cholesterol (table 1, P is more than 0.05), the hawthorn can obviously reduce the blood cholesterol (table 1, P is less than 0.05), and the hawthorn/mulberry combination can obviously reduce the blood cholesterol (table 1, P is less than 0.01). In addition, the hawthorn/mulberry combination showed a synergistic lowering effect on blood cholesterol compared to either mulberry alone or hawthorn (Table 1, P <0.05)
Table 1: the combination of fructus crataegi and Mori fructus has synergistic effect in lowering blood total cholesterol
| Group of | Total Cholesterol TC (mmol/L) |
| Control | 4.06±2.77 |
| High fat | 10.85±2.59a |
| High fat-haw | 6.56±2.29b |
| High fat mulberry | 10.64±1.38 |
| High fat-haw/mulberry | 5.07±1.38b,c,d |
aP<0.01, compared to control group;bP<0.01, compared to the high fat group,cP<0.05, compared with the hawthorn group,dP<0.05, compared to the mulberry group.
Example 2: animal model of high fat diet, hawthorn and mulberry intervention can synergistically lower blood low density lipoprotein cholesterol (LDL-C)
Low density lipoprotein cholesterol: after 12 weeks of continuous feeding, high fat (high fat group) significantly increased blood cholesterol by 1.64mmol/L compared to control group (table 2, P < 0.05). Compared with the high-fat group, the mulberry intervention group has no significant change on the blood LDL-C (Table 2, P >0.05), the hawthorn can significantly reduce the blood LDL-C (Table 2, P <0.05), and the hawthorn/mulberry combination can significantly reduce the blood LDL-C (Table 2, P < 0.01). In addition, the hawthorn/mulberry combination had a synergistic lowering effect on blood LDL-C compared to either mulberry or hawthorn alone (table 2, P < 0.05).
Table 2: the combination of hawthorn and mulberry has synergistic effect of reducing low density lipoprotein cholesterol in blood plasma.
| Group of | Low-density lipoprotein cholesterol LDL (mmol/L) |
| Control | 0.19±0.09 |
| High fat | 1.64±0.19a |
| High fat-haw | 1.18±0.45b |
| High fat mulberry | 1.46±0.22 |
| High fat-haw/mulberry | 0.97±0.51b,c,d |
aP<0.01, compared to control group;bP<0.01, compared to the high fat group,cP<0.05, compared with the hawthorn group,dP<0.05, compared to the mulberry group.
The results of the above studies confirm that: the hawthorn and mulberry composition is used for treating, reducing or preventing cardiovascular disorders associated with hyperlipidemia and/or hypercholesterolemia. The compositions of the present invention may be used in food products, beverages, health foods, functional foods, nutraceutical foods, specialty medical products, nutritional formulas, dietary supplements, and pet foods.
When the hawthorn and mulberry compositions of the present invention are used to produce oral medicines, they can be manufactured into commonly used oral dosage forms such as tablets, capsules, powders, and the like.
Unless otherwise indicated, all numbers expressing quantities of ingredients, cell culture, processing conditions, and so forth used in the specification (including the claims) are to be understood as being modified in all instances by the term "about". Accordingly, unless indicated to the contrary, the numerical parameters are approximations and may vary depending upon the desired properties sought to be obtained by the present invention. The term "at least" preceding a series of elements is to be understood as referring to each element in the series, unless otherwise indicated. Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. The appended claims are intended to cover such equivalents.
The above-mentioned embodiments are intended to illustrate the objects, technical solutions and advantages of the present invention in further detail, and it should be understood that the above-mentioned embodiments are only exemplary embodiments of the present invention, and are not intended to limit the scope of the present invention, and any modifications, equivalent substitutions, improvements and the like made within the spirit and principle of the present invention should be included in the scope of the present invention.
Claims (8)
1. A composition comprises fructus crataegi and Mori fructus at a weight ratio of 5: 4.
2. The composition comprising hawthorn and mulberry according to claim 1, wherein the hawthorn and mulberry are in the form of dry hawthorn powder and dry mulberry powder, respectively;
alternatively, the hawthorn is provided in the form of fresh fruit, jam, dried fruit, fruit powder, or an extract thereof;
alternatively, morous alba is provided in the form of fresh fruit, jam, dried fruit, fruit powder, or extract thereof.
3. The composition comprising hawthorn and mulberry according to any one of claims 1-2, wherein hawthorn and mulberry are the only active ingredients.
4. Composition comprising hawthorn and mulberry according to any of claims 1-3, wherein said composition may be any composition suitable for human or animal consumption selected from: food products, beverages, health foods, functional foods, nutraceutical foods, specialty medical products, nutritional formula products, dietary supplements, and pet foods; alternatively, the composition may be a medicament in oral dosage forms, such as tablets, capsules and powders.
5. Use of a composition comprising hawthorn and mulberry in the manufacture of a medicament for preventing, treating or slowing hyperlipidemia, hypercholesterolemia, and associated cardiovascular disease disorders; wherein the weight ratio of the hawthorn to the mulberry is 5: 4.
6. Use according to claim 5, wherein the cardiovascular disorders associated with hyperlipidemia and/or hypercholesterolemia comprise coronary heart disease, cerebrovascular disease, peripheral arterial disease, rheumatic heart disease, deep vein thrombosis and pulmonary embolism, disorders associated with atherosclerosis.
7. The use according to claim 5 or 6, wherein the hawthorn and the mulberry are in the form of dry hawthorn powder and dry mulberry powder, respectively;
alternatively, the hawthorn is provided in the form of fresh fruit, jam, dried fruit, fruit powder, or an extract thereof;
alternatively, morous alba is provided in the form of fresh fruit, jam, dried fruit, fruit powder, or extract thereof.
8. The use according to any one of claims 5 to 7, wherein hawthorn and mulberry are the only active ingredients.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910593725.9A CN112168874A (en) | 2019-07-03 | 2019-07-03 | Action of hawthorn and mulberry on cardiovascular disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910593725.9A CN112168874A (en) | 2019-07-03 | 2019-07-03 | Action of hawthorn and mulberry on cardiovascular disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112168874A true CN112168874A (en) | 2021-01-05 |
Family
ID=73914954
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910593725.9A Pending CN112168874A (en) | 2019-07-03 | 2019-07-03 | Action of hawthorn and mulberry on cardiovascular disease |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112168874A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113768040A (en) * | 2021-08-31 | 2021-12-10 | 广东省农业科学院蚕业与农产品加工研究所 | Pet feed for improving dyslipidemia of pets and preparation process thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103550333A (en) * | 2013-10-24 | 2014-02-05 | 广西博士海意信息科技有限公司 | Composition for appetizing and reducing blood pressure |
| CN104435772A (en) * | 2014-11-10 | 2015-03-25 | 成都果睿医药科技有限公司 | Hawthorn-containing pharmaceutical composition for reducing blood fat |
-
2019
- 2019-07-03 CN CN201910593725.9A patent/CN112168874A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103550333A (en) * | 2013-10-24 | 2014-02-05 | 广西博士海意信息科技有限公司 | Composition for appetizing and reducing blood pressure |
| CN104435772A (en) * | 2014-11-10 | 2015-03-25 | 成都果睿医药科技有限公司 | Hawthorn-containing pharmaceutical composition for reducing blood fat |
Non-Patent Citations (2)
| Title |
|---|
| 刘继洪: "《常见老年病食疗精选》", 31 October 2015 * |
| 史茂伟等: "脂康颗粒对高龄患者的调脂效果", 《实用医药杂志》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113768040A (en) * | 2021-08-31 | 2021-12-10 | 广东省农业科学院蚕业与农产品加工研究所 | Pet feed for improving dyslipidemia of pets and preparation process thereof |
| CN113768040B (en) * | 2021-08-31 | 2023-10-17 | 广东省农业科学院蚕业与农产品加工研究所 | Pet feed for improving dyslipidemia of pets and preparation process thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kreft | Buckwheat phenolic metabolites in health and disease | |
| US20040076641A1 (en) | Herbal dietary supplement | |
| CN105495258B (en) | A kind of fruit beverage for helping anti-trioxypurine | |
| JP2014514340A (en) | Compositions useful for the treatment of lipid metabolism disorders | |
| EP3064200A1 (en) | Composition comprising natural substances and/or extracts | |
| EP2859896A1 (en) | Pharmaceutical compositions for the treatment of muscular disorders | |
| CN103168815A (en) | Gingko tartary buckwheat cookie and manufacturing method thereof | |
| KR20140017932A (en) | Composition of diabetes-improving effective constituents by fermentation products of the trifoliate orange | |
| KR101672274B1 (en) | Compositions comprising a Viola Herba extract, or an extract of Viola Herba, Persicae Semen, Cinnamomi Ramulus, and Glycyrrhiza spp. for the prevention or treatment of lipid-related cardiovascular diseases and obesity | |
| CN112168874A (en) | Action of hawthorn and mulberry on cardiovascular disease | |
| KR101468551B1 (en) | Composition containing extract of dendropanax morbifera the improvement and remedial of insominia | |
| EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
| KR101731859B1 (en) | A composition for the prevention or treatment of abnormal weight loss comprising Citrus Unshiu Peel extract | |
| KR20140113198A (en) | Pharmaceutical composition and fuctional food composition for prevention or treatment of hyperlipidemia comprising the tsaoko fructus extract | |
| KR101923603B1 (en) | A composition for anti-obesity comprising green tea complex extracts | |
| KR101642176B1 (en) | Composition for enhancing growth and reinforcing immunity | |
| KR102416786B1 (en) | Composition for improvementing, preventing or treating obesity and metabolic diseases comprising fractions or extract of pepper leave | |
| KR102436692B1 (en) | Composition comprising steamed mature silkworm products having silk protein for preventing or treating obesity | |
| KR102404641B1 (en) | Composition for preventing, improving or treating respiratory disease | |
| CN107692087A (en) | A kind of sea cucumber intestine health food of secondary buck | |
| JP3807464B2 (en) | Anti-obesity agent | |
| KR20150031373A (en) | Phamaceutical and food composition for preventing or treating obesity comprising extract of leaf from Hoppophea rhamnoids as effective component | |
| CN101480434A (en) | Compound recipe for reducing blood fat as well as preparation method and application | |
| KR20150005482A (en) | Composition containing extract of dendropanax morbifera the improvement and remedial of insominia | |
| KR101293032B1 (en) | Pharmaceutical composition for treating or preventing obesity comprising sea tangle and sodium butyrate as effective component |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210105 |
|
| RJ01 | Rejection of invention patent application after publication |